caa a22 4500 465790046 CHVBK 20180323112021.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF00177255 doi (NATIONALLICENCE)springer-10.1007/BF00177255 Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer [Elektronische Daten] [David Ettinger, Dianne Finkelstein, Martin Abeloff, Yuang-Chi Chang, Thomas Smith, Martin Oken, John Ruckdeschel] Summary: Fifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or spirogermanium. There was one partial response to N-methylformamide. The median survival times for patients treated with N-MF and spirogermanium were 11.7 and 12.6 weeks respectively. Five patients treated with N-MF experienced severe toxicity while four patients treated with spirogermanium experienced severe and life-threatening toxicity. Kluwer Academic Publishers, 1990 n-methylformamide nationallicence spirogermanium nationallicence small cell lung cancer nationallicence Ettinger David Johns Hopkins Oncology Center, CA 16116, Baltimore, MD aut Finkelstein Dianne Dana-Farber Cancer Institute, Harvard School of Public Health, CA 23318, Boston, MA aut Abeloff Martin Johns Hopkins Oncology Center, CA 16116, Baltimore, MD aut Chang Yuang-Chi University of Rochester Cancer Center, CA 11083, Rochester, NY, USA aut Smith Thomas Tufts New England Medical Center Hospital, CA 07190, Boston, MA aut Oken Martin University of Minnesota, CA 20365, Minneapolis, MN aut Ruckdeschel John Albany Medical College, CA 06594, Albany, NY, USA aut Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 183-185 0167-6997 8:2<183 1990 8 10637 https://doi.org/10.1007/BF00177255 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00177255 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ettinger David Johns Hopkins Oncology Center, CA 16116, Baltimore, MD aut NATIONALLICENCE 700 1- Finkelstein Dianne Dana-Farber Cancer Institute, Harvard School of Public Health, CA 23318, Boston, MA aut NATIONALLICENCE 700 1- Abeloff Martin Johns Hopkins Oncology Center, CA 16116, Baltimore, MD aut NATIONALLICENCE 700 1- Chang Yuang-Chi University of Rochester Cancer Center, CA 11083, Rochester, NY, USA aut NATIONALLICENCE 700 1- Smith Thomas Tufts New England Medical Center Hospital, CA 07190, Boston, MA aut NATIONALLICENCE 700 1- Oken Martin University of Minnesota, CA 20365, Minneapolis, MN aut NATIONALLICENCE 700 1- Ruckdeschel John Albany Medical College, CA 06594, Albany, NY, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 183-185 0167-6997 8:2<183 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer